Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 89

Results For "Ltd"

1104 News Found

NGL Fine-Chem planning greenfield expansion at Tarapur
News | August 16, 2022

NGL Fine-Chem planning greenfield expansion at Tarapur

The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual


Kwality Pharmaceuticals Q1FY23 profit at Rs. 10.52 Cr
News | August 16, 2022

Kwality Pharmaceuticals Q1FY23 profit at Rs. 10.52 Cr

The company has reported total income of Rs. 70.59 crores during the period ended June 30, 2022.


PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital
Biotech | August 16, 2022

PharmaCyte Biotech reaches cooperation agreement with Iroquois Capital

Company appoints five new independent directors to reconstituted board


Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen
News | August 15, 2022

Arbitrator rules in favor of Daiichi Sankyo in dispute with Seagen

All claims made by Seagen regarding Daiichi Sankyo antibody drug conjugates are denied


Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr
News | August 14, 2022

Parmax Pharma posts Q1 FY 23 loss at Rs. 1.31 Cr

The company has reported total income of Rs. 1.56 crores during the period ended June 30, 2022


Hikal shows 17% degrowth in Q1 FY23
News | August 12, 2022

Hikal shows 17% degrowth in Q1 FY23

Pharmaceutical sales de-grew 18% YoY and stood at Rs. 224 crore whereas Crop Protection sales de-grew by 15% at Rs. 154 crore


IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr
News | August 11, 2022

IPCA Laboratories Q1 FY23 consolidated PAT higher at Rs. 143.06 Cr

The company has reported total income of Rs. 1607.85 crores during the period ended June 30, 2022.


Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr
News | August 11, 2022

Zydus Lifesciences Q1 FY23 consolidated PAT up at Rs. 518.3 Cr

The company has reported total income of Rs. 4138.6 crores during the period ended June 30, 2022.


Briefs: Zydus Lifesciences and Kimia Biosciences
News | August 09, 2022

Briefs: Zydus Lifesciences and Kimia Biosciences

The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.


JB Pharma records revenue growth of 30% in Q1 FY23
News | August 09, 2022

JB Pharma records revenue growth of 30% in Q1 FY23

Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23